After Lightning-Paced Tier-1 Sellout, ClinTex’s CTi Token Is Now Trading on KuCoin

PRESS RELEASE. ClinTex is all set to fulfill its promise of reducing cost and time wastage in the medical trials industry, with its CTi token available for public trading on KuCoin on Wednesday. Using the combination of blockchain, artificial intelligence and smart contracts, ClinTex is an innovative medical trial platform that will usher in an era of data sharing, analytics and management in pharmaceutical development that will revolutionize the current industry. The aim: eliminate issues that cause time and resources to be wasted and remove duplication of efforts.

Sharing is Caring

The pharmaceuticals industry is lucrative – an innovative medicine that can tackle a disease is worth billions in sales. However, the industry is littered with high barriers to entry and unfathomable lead times for products. Compounding these problems are the tough trial stages before drugs are approved for use. To offset this huge cost, the pharma industry simply passes on the cost to the public, with the sick paying huge amounts of money for their health. And in ClinTex’s view, this is unacceptable.

ClinTex is leveraging blockchain technology to herald a new age in medical trial data sharing that is secure, efficient and open. Their Clinical Trials Intelligence (CTi) platform utilizes data analytics combined with blockchain technology to address the major inefficiencies in clinical trials. Through this, the estimated $350 billion spent yearly on new medication development can be significantly reduced.

The CTi Platform will also enable better collaboration across the pharmaceutical industry. Currently, there are almost 3,000 studies ongoing that are evaluating Covid-19 treatments and vaccines, but most are working in isolation. Using blockchain technology, CTi will finally provide a way for Big Pharma, small Biotech, academia and independent researchers to collaborate and share key data, allowing for faster clinical trials and less clinical trial…

Read More